Emirates provides passengers with cover for Covid expenses | WeForNews | Latest News, Blogs Emirates provides passengers with cover for Covid expenses – WeForNews | Latest News, Blogs
Connect with us

Health

Emirates provides passengers with cover for Covid expenses

Besides, the airline said that with gradual re-opening of borders over the summer, it has revised booking policies to offer customers more flexibility a nd confidence to plan their travel.

Published

on

Dubai Emirates

New Delhi, July 24 : Gulf carrier Emirates has come out with a confidence booster measure for its passengers as it has started providing free cover for COVID-19 medical expenses and quarantine costs, when they fly to any destination, in any class of travel.

Accordingly, the Dubai-based carrier will cover medical expenses of up to EUR 150,000 or Rs 1.3 crore and quarantine costs of EUR 100 per day or Rs 8,691.10 for 14 days, should they be diagnosed with COVID-19 during their travel, while they are away from home.

“This cover is immediately effective for customers flying on Emirates until 31 October 2020 (first flight to be completed on or before 31 October 2020),” the airline said in a statement.

“It is valid for 31 days from the moment they fly the first sector o f their journey. This means Emirates customers can continue to benefit from the added assurance of this cover, even if they travel onwards to another city after arriving at their Emirates destination.”

According to the airline, passengers do not need to register or fill in any forms before they travel, and they are not obligated to utilise this cover provided by Emirates.

“Any impacted customer who has been diagnosed with COVID-19 during their travel simply has to contact a dedicated hotline to avail of assistance and cover,” the statement said.

Besides, the airline said that with gradual re-opening of borders over the summer, it has revised booking policies to offer customers more flexibility a nd confidence to plan their travel.

“Customers whose travel plans are disrupted by COVID-19 related flight or travel restrictions, can simply hold on to their ticket which will be valid for 24 months and rebook to fly at a later time; request travel vouchers to offset against future Emirates purchases, or request refunds via an online form on Emirates’ website or via their travel booking agent.”

Emirates currently serves over 60 destinations in its network, facilitating travel among the US, Europe, Africa, the Middle East and the Asia Pacific through a connection in Dubai for customers across the world.

Disaster

India’s Covid-19 testing rate lower than other nations, says WHO Chief Scientist

The Chief Scientist of WHO, Soumya Swaminathan, in an interactive session through video conference said,as of now about 28 vaccine candidates for Covid-19 are under clinical trial, of which five are entering Phase-II and over 150 candidates are in pre-clinical trials across the globe.

Published

on

Soumya Swaminathan

Noting that lockdown was a temporary measure to contain the spread of coronavirus, a senior official of the World Health Organisation on Tuesday said India has a low testing rate when compared to some of the countries that are successfully trying to curb it.

The Chief Scientist of WHO, Soumya Swaminathan, in an interactive session through video conference said,as of now about 28 vaccine candidates for Covid-19 are under clinical trial, of which five are entering Phase-II and over 150 candidates are in pre-clinical trials across the globe.

“India as a whole, the testing rates are much lower compared to some of the countries, who have done well like Germany, Taiwan, South Korea, Japan.

Even the United States is testing a huge number of people. So we need to have some benchmark and every public health department needs to have benchmarks on what is the rate of testing per lakh or per million, what is the test positivity rate,” she said.

Without adequate number of tests, fighting the virus is like “fighting fire blindfolded,” she pointed out.

According to Swaminathan, the number of tests being conducted is not adequate if the Covid-19 test positivity rate is above five per cent.

Governments need to constantly monitor the availability of beds, quarantine facilities, ICUs and oxygen supplies in district hospitals.

“So there is a set of 8 to 10 indicators that the government needs to keep a close watch on. And you can ramp up or ramp down based on what you are seeing on the ground,” she said.

Observing that the scientists’ community was still studying the body’s immune response to coronavirus and the next 12 months were crucial to put in place the public health and social measures, she said the virus has spread to every country in the world and “established community transmission”.

“We know that lockdowns are temporary measures or a temporary measure which reduces the spread because it prevents people from getting closer together and the idea of the lockdown is to buy time for the government to put in place the system needed to tackle the virus,” the WHO official said.

On the ongoing vaccine trials, she said the WHO has issued guidelines on it and if the efficacy rate of the vaccine is 70 percent, then it is considered to be a good one.

On the COVAX facility, a mechanism designed to guarantee rapid, fair and equitable access to COVID-19 vaccines worldwide, Swaminathan said by the end of 2021 it is aimed to deliver two billion doses of safe, effective vaccines that have passed regulatory approval and/or WHO prequalification.

All the 194 member countries of the WHO need to come together and take a decision on the way they want to proceed for the equitable and fair distribution of vaccine (once successfully comes out) and other products that are being developed for Covid-19, she opined.

Krishna Ella, Chairman and Managing Director of Bharat Biotech, which is into developing Covaxin, a vaccine candidate for Covid-19,said the Centre needs to decetralise some of the regulating authorities such as Central Drugs Standard Control Organisation (CDSCO for faster approvals.

Telangana Minister for IT and Industries KT Rama Rao acted as a moderator for the session titled The Vaccine Race- Balancing Science and Urgency.

Continue Reading

Health

PGI-Chandigarh among 17 trial sites for Oxford vaccine Covishield

The permission was granted after the Serum institute satisfied certain requirements sought by the Drug Controller in the design of the proposal.

Published

on

By

Covid 19 Vaccine

Chandigarh, Aug 4 : The PGI Hospital here is among the 17 trial sites in India for conducting the second and third phases of human clinical trials of Covishield, the potential vaccine developed by Oxford University, its director said on Tuesday.

The trials would involve administration of the vaccine to 1,600 healthy adults across 17 sites.

Postgraduate Institute of Medical Education and Research (PGIMER) Director Jagat Ram said, “It’s an honour to be entrusted with this vital responsibility of being one of the sites for phase two and three trials on Covishield vaccine.

“The results of phase one trials in the UK have been encouraging and did not present any serious adverse side effects. Phase two and three trials will be done on a larger human population to see its efficacy and requisite protection against COVID-19 in humans.”

Further detailing, the Director added, “As the results of the trials will have far reaching impact, we will strengthen our capacities, wherever required, to come out with tangible outcomes.

“A core group will be constituted to work out the modalities and comprehensive plan along with timelines to meet the desired expectations of Drugs Controller General of India and contribute towards containing the pandemic to the best of our abilities.”

Earlier, a committee of experts on COVID-19 under Central Drugs Standard Control Organisation (CDSCO) had recommended the Drugs Controller General of India (DCGI) to grant approval to the Serum Institute of India (SII) for conducting the Phase two and three trials.

The permission was granted after the Serum institute satisfied certain requirements sought by the Drug Controller in the design of the proposal.

In addition to PGIMER Chandigarh, the other sites for trials include AIIMS in Delhi, ABJ Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, AIIMS in Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysuru.

Continue Reading

Disaster

COVID-19 pandemic “once in a century”, but still “in our hands”: WHO

“I’m not saying there is no solution now. Whatever happens in the next few months or years, I also believe that it’s in our hands,” he said.

Published

on

By

Tedros Adhanom Ghebreyesus WHO

Geneva, Aug 4 : The chief of the World Health Organization (WHO) said that the COVID-19 pandemic is “a once-in-a-century health crisis,” but it is still “in our hands.”

WHO Director-General Tedros Adhanom Ghebreyesus said at a virtual press conference on Monday that the world has never seen anything like this pandemic for decades, and its effects might last for decades more, Xinhua news agency reported.

“Since we started probably recording, this is the first ever coronavirus-caused pandemic which has two dangerous combinations: it moves fast, and at the same time it’s a killer,” the WHO chief explained.

However, he noted, although the crisis is very severe, there are still solutions and hopes.

“I’m not saying there is no solution now. Whatever happens in the next few months or years, I also believe that it’s in our hands,” he said.

“Since the outbreak started, many countries have shown that it can be controlled, or serious transmission can be suppressed,” Tedros said, adding that he has mentioned many such countries in the past, including Spain, Italy, China and South Korea.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.